丝状病毒中和单克隆抗体的结构基础。
The structural basis for filovirus neutralization by monoclonal antibodies.
机构信息
Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA; Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
出版信息
Curr Opin Immunol. 2018 Aug;53:196-202. doi: 10.1016/j.coi.2018.05.001. Epub 2018 Jun 22.
Abstract
Filoviruses, including ebolaviruses and marburgviruses, are the causative agents of highly lethal disease outbreaks. The 2013-2016 Ebola virus outbreak was responsible for >28000 infections and >11000 deaths. Although there are currently no licensed vaccines or therapeutics for any filovirus-induced disease, monoclonal antibodies (mAbs) are among the most promising options for therapeutic development. Hundreds of mAbs have been isolated from human survivors of filovirus infections that target the viral spike glycoprotein (GP). The binding, neutralization, and cross-reactivity of many of these mAbs has been determined. Several mAbs have been characterized structurally, and this information has been crucial for strategizing therapeutic and vaccine design. Here we present an overview of the structural features of the neutralizing/protective epitopes on filovirus glycoproteins.
摘要
丝状病毒，包括埃博拉病毒和马尔堡病毒，是引起高度致命疾病爆发的病原体。2013-2016 年埃博拉病毒爆发导致超过 28000 例感染和超过 11000 人死亡。尽管目前尚无针对任何丝状病毒引起的疾病的许可疫苗或治疗方法，但单克隆抗体 (mAb) 是治疗开发最有前途的选择之一。已经从丝状病毒感染的人类幸存者中分离出数百种针对病毒刺突糖蛋白 (GP) 的 mAb。已经确定了其中许多 mAb 的结合、中和和交叉反应性。已经对几种 mAb 进行了结构表征，这些信息对于制定治疗和疫苗设计策略至关重要。在这里，我们介绍了丝状病毒糖蛋白上中和/保护性表位的结构特征概述。
相似文献
1
The structural basis for filovirus neutralization by monoclonal antibodies.丝状病毒中和单克隆抗体的结构基础。
Curr Opin Immunol. 2018 Aug;53:196-202. doi: 10.1016/j.coi.2018.05.001. Epub 2018 Jun 22.
2
Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.靶向丝状病毒糖蛋白内新型保守表位的猕猴单克隆抗体。
J Virol. 2015 Oct 14;90(1):279-91. doi: 10.1128/JVI.02172-15. Print 2016 Jan 1.
3
Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses.泛埃博拉病毒和泛丝状病毒小鼠单克隆抗体：对埃博拉病毒和苏丹病毒的保护作用
J Virol. 2015 Oct 14;90(1):266-78. doi: 10.1128/JVI.02171-15. Print 2016 Jan 1.
4
Generation and Characterization of Anti-Filovirus Nucleoprotein Monoclonal Antibodies.抗丝状病毒核蛋白单克隆抗体的产生与鉴定。
Viruses. 2019 Mar 14;11(3):259. doi: 10.3390/v11030259.
5
Chimeric Filoviruses for Identification and Characterization of Monoclonal Antibodies.用于单克隆抗体鉴定与表征的嵌合丝状病毒
J Virol. 2016 Mar 28;90(8):3890-3901. doi: 10.1128/JVI.00101-16. Print 2016 Apr.
6
A Single-Vector, Single-Injection Trivalent Filovirus Vaccine: Proof of Concept Study in Outbred Guinea Pigs.一种单载体、单次注射的三价丝状病毒疫苗：远交豚鼠的概念验证研究
J Infect Dis. 2015 Oct 1;212 Suppl 2(Suppl 2):S384-8. doi: 10.1093/infdis/jiv126. Epub 2015 May 9.
7
Design and evaluation of bi- and trispecific antibodies targeting multiple filovirus glycoproteins.针对多种丝状病毒糖蛋白的双特异性和三特异性抗体的设计与评估。
J Biol Chem. 2018 Apr 20;293(16):6201-6211. doi: 10.1074/jbc.RA117.001627. Epub 2018 Mar 2.
8
Designing and testing broadly-protective filoviral vaccines optimized for cytotoxic T-lymphocyte epitope coverage.设计和测试针对细胞毒性 T 淋巴细胞表位覆盖范围进行优化的广泛保护性丝状病毒疫苗。
PLoS One. 2012;7(10):e44769. doi: 10.1371/journal.pone.0044769. Epub 2012 Oct 3.
9
Comparative analysis of serologic cross-reactivity using convalescent sera from filovirus-experimentally infected fruit bats.使用来自经实验感染丝状病毒的果蝠的恢复期血清进行血清学交叉反应的比较分析。
Sci Rep. 2019 Apr 30;9(1):6707. doi: 10.1038/s41598-019-43156-z.
10
Design and characterization of protective pan-ebolavirus and pan-filovirus bispecific antibodies.保护性泛埃博拉病毒和泛丝状病毒双特异性抗体的设计与表征
PLoS Pathog. 2024 Apr 11;20(4):e1012134. doi: 10.1371/journal.ppat.1012134. eCollection 2024 Apr.
引用本文的文献
1
Soluble CD4 inhibits Ebola virus infection by targeting endosomal receptor-binding site.可溶性CD4通过靶向内体受体结合位点抑制埃博拉病毒感染。
iScience. 2025 May 2;28(6):112573. doi: 10.1016/j.isci.2025.112573. eCollection 2025 Jun 20.
2
Rational design of next-generation filovirus vaccines with glycoprotein stabilization, nanoparticle display, and glycan modification.通过糖蛋白稳定化、纳米颗粒展示和聚糖修饰对下一代丝状病毒疫苗进行合理设计。
bioRxiv. 2025 Mar 2:2025.03.02.641072. doi: 10.1101/2025.03.02.641072.
3
Identification of Filovirus Entry Inhibitors from Marine Fungus-Derived Indole Alkaloids.从海洋真菌衍生的吲哚生物碱中鉴定丝状病毒进入抑制剂。
Mar Drugs. 2025 Jan 3;23(1):23. doi: 10.3390/md23010023.
4
Pan-ebolavirus protective therapy by two multifunctional human antibodies.两株多功能人源抗体对泛埃博拉病毒的保护作用治疗。
Cell. 2021 Oct 28;184(22):5593-5607.e18. doi: 10.1016/j.cell.2021.09.035.
5
Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma.蛋白基因组分析鉴定出埃博拉病毒糖蛋白上两个中和抗体的主要弱点区域，这些抗体存在于恢复期人血浆中。
Front Immunol. 2021 Jul 16;12:706757. doi: 10.3389/fimmu.2021.706757. eCollection 2021.
6
Identification of filovirus entry inhibitors targeting the endosomal receptor NPC1 binding site.鉴定靶向内体受体 NPC1 结合位点的丝状病毒进入抑制剂。
Antiviral Res. 2021 May;189:105059. doi: 10.1016/j.antiviral.2021.105059. Epub 2021 Mar 8.
7
Ebola virus antibody decay-stimulation in a high proportion of survivors.高比例幸存者体内埃博拉病毒抗体衰减刺激。
Nature. 2021 Feb;590(7846):468-472. doi: 10.1038/s41586-020-03146-y. Epub 2021 Jan 27.
8
An immunotoxin targeting Ebola virus glycoprotein inhibits Ebola virus production from infected cells.一种针对埃博拉病毒糖蛋白的免疫毒素可抑制感染细胞中埃博拉病毒的产生。
PLoS One. 2021 Jan 7;16(1):e0245024. doi: 10.1371/journal.pone.0245024. eCollection 2021.
9
A biaryl sulfonamide derivative as a novel inhibitor of filovirus infection.作为一种新型丝状病毒感染抑制剂的双芳基磺酰胺衍生物。
Antiviral Res. 2020 Nov;183:104932. doi: 10.1016/j.antiviral.2020.104932. Epub 2020 Sep 15.
10
Therapeutic strategies to target the Ebola virus life cycle.针对埃博拉病毒生命周期的治疗策略。
Nat Rev Microbiol. 2019 Oct;17(10):593-606. doi: 10.1038/s41579-019-0233-2. Epub 2019 Jul 24.
本文引用的文献
1
Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection.针对埃博拉病毒 GP 的单克隆抗体的系统分析定义了有助于保护的特征。
Cell. 2018 Aug 9;174(4):938-952.e13. doi: 10.1016/j.cell.2018.07.033.
2
The Marburgvirus-Neutralizing Human Monoclonal Antibody MR191 Targets a Conserved Site to Block Virus Receptor Binding.马尔堡病毒中和性人源单克隆抗体 MR191 靶向一个保守位点以阻断病毒受体结合。
Cell Host Microbe. 2018 Jan 10;23(1):101-109.e4. doi: 10.1016/j.chom.2017.12.003.
3
Structure of the Ebola virus envelope protein MPER/TM domain and its interaction with the fusion loop explains their fusion activity.埃博拉病毒包膜蛋白 MPER/TM 结构域及其与融合环的相互作用解释了它们的融合活性。
Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):E7987-E7996. doi: 10.1073/pnas.1708052114. Epub 2017 Sep 5.
4
Novel Cross-Reactive Monoclonal Antibodies against Ebolavirus Glycoproteins Show Protection in a Murine Challenge Model.针对埃博拉病毒糖蛋白的新型交叉反应性单克隆抗体在小鼠攻毒模型中显示出保护作用。
J Virol. 2017 Jul 27;91(16). doi: 10.1128/JVI.00652-17. Print 2017 Aug 15.
5
Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability.免疫引发的广泛保护性抗体揭示埃博拉病毒融合环为易损位点。
Cell. 2017 May 18;169(5):891-904.e15. doi: 10.1016/j.cell.2017.04.038.
6
Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses.一名人类幸存者的抗体确定了针对埃博拉病毒广泛保护的易损位点。
Cell. 2017 May 18;169(5):878-890.e15. doi: 10.1016/j.cell.2017.04.037.
7
Structure of the Ebola virus glycoprotein spike within the virion envelope at 11 Å resolution.埃博拉病毒糖蛋白刺突在病毒包膜中的结构，分辨率为 11Å。
Sci Rep. 2017 Apr 11;7:46374. doi: 10.1038/srep46374.
8
Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody.用人源单克隆抗体对非人灵长类动物进行马尔堡病毒和拉文病毒感染的治疗性处理。
Sci Transl Med. 2017 Apr 5;9(384). doi: 10.1126/scitranslmed.aai8711.
9
Antibody-dependent-cellular-cytotoxicity-inducing antibodies significantly affect the post-exposure treatment of Ebola virus infection.抗体依赖的细胞毒性诱导抗体显著影响埃博拉病毒感染的暴露后治疗。
Sci Rep. 2017 Mar 30;7:45552. doi: 10.1038/srep45552.
10
Structures of Ebola virus GP and sGP in complex with therapeutic antibodies.埃博拉病毒 GP 和 sGP 与治疗性抗体复合物的结构。
Nat Microbiol. 2016 Aug 8;1(9):16128. doi: 10.1038/nmicrobiol.2016.128.
Zotero 插件